JAK inhibitors for hair loss represent a significant advance in the treatment of severe alopecia areata, an autoimmune condition that can cause extensive or total hair loss. By targeting the JAK-STAT signalling pathway, these medicines help restore the immune environment around hair follicles, allowing regrowth in patients who have not responded to conventional therapies. In the UK, oral baricitinib and oral ritlecitinib are the only JAK inhibitors currently licensed for this indication, both recommended by NICE for severe disease in eligible patients. This article explains how they work, who may benefit, their safety profile, and what to discuss with your GP or dermatologist.
Summary: JAK inhibitors for hair loss — specifically oral baricitinib and oral ritlecitinib — are licensed in the UK for severe alopecia areata and work by blocking the JAK-STAT immune signalling pathway to allow hair follicle regrowth.
- Baricitinib (JAK1/JAK2 inhibitor) and ritlecitinib (JAK3/TEC kinase inhibitor) are the only JAK inhibitors licensed for alopecia areata in the UK; tofacitinib is not licensed for this indication.
- Both medicines are recommended by NICE for adults with severe alopecia areata (SALT score ≥50); ritlecitinib is also approved for adolescents aged 12 and over.
- The MHRA has issued class-level safety guidance highlighting risks of serious infection, major cardiovascular events, venous thromboembolism, and malignancy, particularly in higher-risk patients.
- Comprehensive baseline screening — including FBC, TB testing, hepatitis serology, and lipid profile — is required before starting treatment, with ongoing blood monitoring throughout.
- JAK inhibitors are not recommended during pregnancy or breastfeeding; effective contraception is required during treatment and for a specified period after stopping.
- Hair regrowth may not be sustained after stopping treatment; relapse following discontinuation has been observed in clinical studies.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
How JAK Inhibitors Work to Treat Hair Loss
JAK inhibitors block the JAK-STAT signalling pathway, suppressing interferon-gamma and interleukin-15 activity to restore immune privilege at the hair follicle and allow dormant follicles to re-enter the growth phase.
Janus kinase (JAK) inhibitors represent a relatively new class of targeted immunomodulatory medicines that work by blocking specific intracellular signalling pathways involved in immune-mediated inflammation. The JAK-STAT pathway plays a central role in transmitting signals from cytokines — chemical messengers released by immune cells — that can, in certain conditions, trigger the immune system to attack hair follicles. By inhibiting JAK enzymes, these medicines interrupt this inflammatory cascade and help restore a more tolerant immune environment around the follicle.
Different JAK inhibitors have distinct selectivity profiles. Baricitinib primarily inhibits JAK1 and JAK2, whilst ritlecitinib is a selective inhibitor of JAK3 and the TEC family of kinases. This difference in selectivity is clinically relevant and contributes to differences in their safety and interaction profiles. Tofacitinib (a JAK1/JAK3 inhibitor) is sometimes referenced in the scientific literature on alopecia areata but is not licensed for this indication in the United Kingdom and its use would be considered off-label.
In the context of hair loss, the primary mechanism of interest is the suppression of interferon-gamma and interleukin-15 signalling, both of which are implicated in the collapse of immune privilege at the hair follicle. Under normal circumstances, hair follicles are partially shielded from immune attack. In conditions such as alopecia areata, this privilege breaks down, exposing follicles to cytotoxic T-cell activity. JAK inhibitors help re-establish this protective environment, allowing dormant follicles to re-enter the active growth (anagen) phase.
Not sure if this is normal? Chat with one of our pharmacists →
In the UK, the only JAK inhibitors currently licensed for alopecia areata are oral baricitinib and oral ritlecitinib. Topical JAK inhibitor formulations (for example, topical ruxolitinib or topical tofacitinib) are not licensed for alopecia areata in the UK and any such use would be off-label. It is important to note that JAK inhibitors do not permanently cure the underlying autoimmune process; hair regrowth may be sustained only whilst treatment continues, and relapse following discontinuation has been observed in clinical studies.
| Feature | Baricitinib (Olumiant) | Ritlecitinib (Litfulo) |
|---|---|---|
| Mechanism / Selectivity | JAK1 and JAK2 inhibitor | Selective JAK3 and TEC family kinase inhibitor |
| Licensed Indication (UK) | Severe alopecia areata in adults | Severe alopecia areata in adults and adolescents aged ≥12 years |
| Available Dose | 2 mg and 4 mg oral tablets | 50 mg oral capsules |
| NICE Recommendation | NICE TA878 (2023); SALT score ≥50, inadequate response to prior treatments | NICE TA985 (2024); first licensed option for adolescents with severe disease |
| Key Drug Interactions | OAT3 substrate; probenecid increases exposure, may require dose reduction | CYP3A substrate; strong CYP3A inhibitors or inducers may alter exposure |
| Notable Monitoring Requirements | FBC, LFTs, lipids, renal function (dose adjustment needed in renal impairment), TB screening | FBC, LFTs, lipids, TB screening, hepatitis B/C serology; consult SmPC |
| Key MHRA Safety Warnings | Serious infections, MACE, VTE, malignancy, anaemia; avoid in high-risk patients where alternatives exist; not recommended in pregnancy or breastfeeding | |
Which Hair Loss Conditions May Respond to Treatment
Alopecia areata — including alopecia totalis and alopecia universalis — has the strongest evidence base for JAK inhibitor therapy; scarring alopecias and androgenetic alopecia are not licensed indications in the UK.
JAK inhibitors have been most extensively studied in alopecia areata, an autoimmune condition in which the immune system mistakenly targets hair follicles, resulting in patchy or, in severe cases, complete scalp and body hair loss. Alopecia areata affects approximately 2% of the population at some point in their lifetime and can have a significant psychological impact. Historically, treatment options were limited and often insufficiently effective for moderate-to-severe disease, making JAK inhibitors a meaningful therapeutic advance.
Clinical trial data — including the pivotal BRAVE-AA1 and BRAVE-AA2 randomised controlled trials for baricitinib and the ALLEGRO phase 2b/3 trials for ritlecitinib — have demonstrated statistically significant and clinically meaningful hair regrowth in adults with severe alopecia areata. Patients with alopecia totalis (complete scalp hair loss) and alopecia universalis (complete body hair loss) — the most severe subtypes — have also shown responses, though outcomes tend to be more variable. Response is generally assessed using the Severity of Alopecia Tool (SALT) score, where a lower score indicates less hair loss.
Beyond alopecia areata, there is emerging interest in JAK inhibitors for other inflammatory hair loss conditions, including:
-
Lichen planopilaris — a scarring alopecia with an inflammatory basis
-
Frontal fibrosing alopecia — a progressive scarring condition predominantly affecting post-menopausal women
However, evidence for these conditions remains limited and is largely based on small case series or observational data of low methodological quality. There is no licensed indication for JAK inhibitors in scarring alopecias in the UK, and any such use would be off-label and should only be considered under specialist supervision. Androgenetic alopecia (male or female pattern hair loss) is not currently an established indication for JAK inhibitor therapy.
Importantly, scarring alopecias such as lichen planopilaris and frontal fibrosing alopecia can cause permanent, irreversible hair loss if not identified and managed promptly. If you notice symptoms such as scalp pain, burning, itching, redness, or scaling around hair follicles — particularly at the hairline — you should seek an urgent referral to a consultant dermatologist. Early specialist assessment is essential to limit permanent follicular damage.
Potential Side Effects and Safety Considerations
Key risks include serious infections (including herpes zoster reactivation), major cardiovascular events, venous thromboembolism, and malignancy; comprehensive baseline screening and regular monitoring are mandatory throughout treatment.
As with all immunomodulatory medicines, JAK inhibitors carry a recognised safety profile that requires careful consideration before initiation and ongoing monitoring during treatment. Because these agents suppress aspects of immune function, the most clinically significant risks relate to infection susceptibility. Upper respiratory tract infections, urinary tract infections, and reactivation of latent infections — particularly herpes zoster (shingles) — have been reported across clinical trials and post-marketing surveillance data reviewed by the MHRA and EMA.
The MHRA has issued class-level safety guidance (Drug Safety Update, 2023) highlighting that JAK inhibitors carry risks of:
-
Serious infections, including opportunistic infections
-
Major adverse cardiovascular events (MACE), including heart attack and stroke, particularly in patients with pre-existing cardiovascular risk factors
-
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism
-
Malignancy, including lymphoma and non-melanoma skin cancer, especially with long-term use
-
Anaemia and changes in blood counts
The MHRA advises that JAK inhibitors should be used only when no suitable alternative treatment is available in patients who are aged 65 years or over, are current or long-term ex-smokers, have an increased risk of major cardiovascular events, or have an increased risk of malignancy. Prescribers and patients should discuss these individual risk factors before starting treatment.
These risks are more extensively characterised in older JAK inhibitors used at higher doses for rheumatoid arthritis; the absolute risk in younger, otherwise healthy patients treated for alopecia areata at licensed doses may differ. Nevertheless, comprehensive baseline screening is required before commencing therapy, including:
-
Full blood count (FBC), liver function tests (LFTs), renal function, and lipid profile
-
Tuberculosis screening (IGRA or Mantoux test)
-
Hepatitis B and C serology (with appropriate management for carriers)
-
HIV testing where clinically indicated
-
Pregnancy test in women of childbearing potential
-
Review of immunisation status
Ongoing monitoring should follow the relevant Summary of Product Characteristics (SmPC): lipid levels should be checked at approximately 12 weeks after starting treatment and periodically thereafter; FBC and LFTs should be monitored at regular intervals. For baricitinib, renal function monitoring is particularly important as dose adjustment is required in renal impairment. Prescribers should consult the individual SmPCs (available via the MHRA/EMC) for full monitoring schedules and dose-interruption thresholds.
Drug interactions should be reviewed carefully. Ritlecitinib is metabolised via CYP3A and co-administration with strong CYP3A inhibitors or inducers may alter drug exposure. Baricitinib is a substrate of OAT3 transporters; co-administration with OAT3 inhibitors (such as probenecid) increases baricitinib exposure and may require dose reduction. Patients should inform their clinician of all medicines, including over-the-counter products and herbal supplements.
Worried about interactions with other medications? Speak to one of our pharmacists →
Pregnancy, breastfeeding, and contraception: JAK inhibitors are not recommended during pregnancy or breastfeeding. Women of childbearing potential must use effective contraception during treatment and for a period after stopping, as specified in the relevant SmPC. Pregnancy intentions should be discussed with a clinician before starting treatment, and any unplanned pregnancy during treatment should be reported to the prescribing team immediately.
Common but less serious side effects include acne, headache, nausea, and nasopharyngitis. Patients should be advised to report any signs of infection promptly and to avoid live vaccines during treatment. The recombinant (non-live) herpes zoster vaccine may be considered prior to starting therapy where clinically appropriate, in line with MHRA guidance and NHS immunisation recommendations; patients should discuss their vaccination status with their clinician before treatment begins.
Patients and carers are encouraged to report any suspected side effects directly to the MHRA via the Yellow Card Scheme (available at yellowcard.mhra.gov.uk), in addition to informing their healthcare team.
NICE Guidance and Prescribing Eligibility in the NHS
NICE recommends baricitinib (TA878) and ritlecitinib (TA985) for severe alopecia areata (SALT score ≥50) in patients who have not responded to other treatments, initiated and supervised by a consultant dermatologist.
In the United Kingdom, access to JAK inhibitors for hair loss on the NHS is governed by NICE technology appraisal (TA) guidance.
Baricitinib (Olumiant, 2 mg and 4 mg) received a positive NICE recommendation (NICE TA878, published 2023) for the treatment of severe alopecia areata in adults. This was the first systemic treatment to receive a positive NICE recommendation specifically for this condition. The guidance specifies that baricitinib is recommended only when:
-
The patient has severe alopecia areata, defined as a SALT score of 50 or above (indicating ≥50% scalp hair loss)
-
The condition has not responded adequately to other treatments
-
Treatment is initiated and supervised by a consultant dermatologist
NICE also specifies continuation and stopping criteria: treatment should be reviewed at an appropriate interval (as defined in the TA) and discontinued in patients who do not achieve a meaningful reduction in SALT score by the specified time point. Patients and clinicians should refer to the full NICE TA878 guidance for the precise response thresholds and review intervals.
Ritlecitinib (Litfulo, 50 mg), a selective JAK3/TEC family kinase inhibitor, received MHRA and EMA approval in 2023 for severe alopecia areata in adults and adolescents aged 12 years and over. NICE issued a positive recommendation for ritlecitinib (NICE TA985, published 2024), making it the first approved option for adolescents with severe disease — a group previously without licensed systemic treatment options. As with baricitinib, NICE specifies eligibility criteria, review intervals, and stopping rules; the full TA should be consulted for details.
It is important to note that prescribing eligibility criteria are specific and not all patients with alopecia areata will qualify for NHS-funded treatment. Patients with mild-to-moderate disease, or those who have not yet tried conventional treatments, are unlikely to meet the threshold for JAK inhibitor therapy under current guidance. Treatment must be initiated and overseen by a consultant dermatologist in an appropriate specialist setting, following local NHS funding pathways. Private prescribing outside NICE criteria may be available but is subject to individual clinical assessment and cost considerations. Patients are encouraged to discuss their eligibility with a dermatologist rather than assuming access based on diagnosis alone.
What to Discuss With Your GP or Dermatologist
Patients should discuss their SALT score, previous treatments, medical history, current medicines, vaccination status, and contraception needs before starting JAK inhibitor therapy, as eligibility criteria are specific and monitoring is ongoing.
If you are experiencing significant hair loss and are wondering whether JAK inhibitors might be appropriate for you, the first step is to seek a formal diagnosis from your GP, who may refer you to a consultant dermatologist. Not all hair loss is autoimmune in origin, and an accurate diagnosis is essential before any treatment pathway is considered.
When to seek urgent referral: If you notice scalp pain, burning, itching, persistent redness, scaling around hair follicles, or follicular pustules — particularly at the hairline or temples — please contact your GP promptly. These may be signs of a scarring alopecia, which can cause permanent hair loss if not treated early. Children with patchy hair loss and scalp scaling should also be assessed urgently to exclude tinea capitis (scalp ringworm), which requires a different treatment approach entirely.
Your dermatologist will assess the pattern, extent, and duration of hair loss, and may perform a scalp biopsy or blood tests to confirm the diagnosis and rule out other causes. When discussing JAK inhibitors with your clinician, it is helpful to raise the following points:
-
Your SALT score — understanding the severity of your alopecia and whether it meets the threshold for treatment
-
Previous treatments tried — including topical corticosteroids, intralesional steroid injections, immunotherapy (diphencyprone), or systemic immunosuppressants
-
Your medical history — particularly any history of cardiovascular disease, blood clots, recurrent infections, liver or kidney problems, or malignancy, which may affect eligibility or require additional caution
-
Your medicines — including all prescription medicines, over-the-counter products, and herbal supplements, to allow your clinician to check for potential interactions
-
Vaccination status — especially regarding herpes zoster and other recommended vaccines prior to starting treatment
-
Pregnancy, contraception, and breastfeeding — if you are pregnant, planning a pregnancy, or breastfeeding, this must be discussed before starting treatment, as JAK inhibitors are not recommended in these circumstances and effective contraception is required during therapy
-
Expectations and monitoring — understanding that response to treatment may take several months, that regular blood tests are required throughout treatment, and that hair loss may recur if treatment is stopped
The psychological impact of significant hair loss should not be underestimated. If you are struggling emotionally, please mention this to your GP or dermatologist. Support is available through NHS mental health services and patient organisations such as Alopecia UK (alopeciaonline.org.uk), which provides peer support and information for people affected by all forms of alopecia.
Patients should contact their GP or dermatology team promptly if they develop signs of infection, unexplained breathlessness, leg swelling, or chest pain whilst on treatment, as these may indicate serious adverse effects requiring urgent review. Suspected side effects should also be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk. Open, informed dialogue with your healthcare team is the most effective way to ensure that treatment decisions are safe, appropriate, and aligned with your individual circumstances and preferences.
Frequently Asked Questions
How long does it take for JAK inhibitors to work for hair loss?
Hair regrowth with JAK inhibitors for alopecia areata typically takes several months, and NICE guidance specifies review points to assess whether a meaningful response has been achieved. Patients who do not meet the defined response threshold by the specified time point should have treatment discontinued in line with NICE stopping rules.
Will my hair loss come back if I stop taking a JAK inhibitor?
Relapse of alopecia areata after stopping JAK inhibitor treatment has been observed in clinical studies, as these medicines manage rather than cure the underlying autoimmune process. Patients should discuss the long-term treatment plan and the likelihood of relapse with their dermatologist before starting therapy.
Can I get JAK inhibitors for hair loss on the NHS?
NHS-funded JAK inhibitors for hair loss are available only for adults with severe alopecia areata (SALT score of 50 or above) who have not responded adequately to other treatments, under NICE TA878 (baricitinib) and NICE TA985 (ritlecitinib). Treatment must be initiated and supervised by a consultant dermatologist, and patients with mild-to-moderate disease are unlikely to meet the eligibility threshold.
What is the difference between baricitinib and ritlecitinib for alopecia areata?
Baricitinib inhibits JAK1 and JAK2, whilst ritlecitinib selectively inhibits JAK3 and the TEC family of kinases, giving them different selectivity, safety, and drug interaction profiles. A key practical difference is that ritlecitinib is licensed for adolescents aged 12 and over, whereas baricitinib is currently approved only for adults.
Are JAK inhibitors safe to take if I have a history of heart disease or blood clots?
The MHRA advises particular caution with JAK inhibitors in patients with pre-existing cardiovascular risk factors, a history of venous thromboembolism, or those aged 65 and over, recommending use only when no suitable alternative is available. Your dermatologist will assess your individual risk profile before prescribing and should discuss these risks with you in detail.
Can I use a topical JAK inhibitor for hair loss instead of taking tablets?
Topical JAK inhibitor formulations, such as topical ruxolitinib or topical tofacitinib, are not licensed for alopecia areata in the UK, and any such use would be considered off-label. Only oral baricitinib and oral ritlecitinib currently hold a UK licence for this indication and have received positive NICE recommendations.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
